Summary

Eligibility
for people ages 8 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around
Principal Investigator
by Jacque Duncan, MD
Headshot of Jacque Duncan
Jacque Duncan

Description

Summary

The overall goal of this project funded by the Foundation Fighting Blindness is to characterize the natural history of disease progression in patients with USH2A related retinal degeneration associated with congenital hearing loss (Usher syndrome type 2a) or non-syndromic retinitis pigmentosa (RP39).

RUSH2A Extension Study: The purpose of this addendum is to extend RUSH2A to 7- and 9-year visits, with the goal to use longer term data to further develop and support early candidate endpoints as possible clinical trial outcomes.

Details

Keywords

Usher Syndrome, Type 2A, Retinitis Pigmentosa 39, Usher Syndromes, Retinitis, Retinitis Pigmentosa, Retinal Degeneration

Eligibility

Locations

  • UCSF
    San Francisco California 94143-0344 United States
  • Moran Eye Center, University of Utah
    Salt Lake City Utah 84107 United States

Lead Scientist at UCSF

  • Jacque Duncan, MD
    Retinitis pigmentosa (RP) affects about 1 in 3,500 people worldwide. Age-related macular degeneration (AMD) affects as many as 1 in 4 people by the age of 75 and is the leading cause of blindness in people over age 50 in the United States. Both RP and AMD have a hereditary basis, and currently, there is no cure for either of these types of hereditary retinal degeneration.

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Jaeb Center for Health Research
ID
NCT03146078
Study Type
Observational
Participants
About 127 people participating
Last Updated